This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Esparís-Ogando, A. Articles by Pandiella, A. Search for Related Content PubMed PubMed Citation Articles by Esparís-Ogando, A. Articles by Pandiella, A.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, January 2002, p. 270-285, Vol. 22, No. 1
0270-7306/01/$04.00+0     DOI: 10.1128/MCB.22.1.270-285.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Erk5 Participates in Neuregulin Signal Transduction and Is Constitutively Active in Breast Cancer Cells Overexpressing ErbB2

Instituto de Microbiología Bioquímica and Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Científicas, Universidad de Salamanca, Salamanca,¹ Instituto Investigaciones Biomédicas, Madrid, Spain²

Received 11 June 2001/ Accepted 8 October 2001

The four receptor tyrosine kinases of the ErbB family play essential roles in several physiological processes and have also been implicated in tumor generation and/or progression. Activation of ErbB1/EGFR is mainly triggered by epidermal growth factor (EGF) and other related ligands, while activation of ErbB2, ErbB3, and ErbB4 receptors occurs by binding to another set of EGF-like ligands termed neuregulins (NRGs). Here we show that the Erk5 mitogen-activated protein kinase (MAPK) pathway participates in NRG signal transduction. In MCF7 cells, NRG activated Erk5 in a time- and dose-dependent fashion. The action of NRG on Erk5 was dependent on the kinase activity of ErbB receptors but was independent of Ras. Expression in MCF7 cells of a dominant negative form of Erk5 resulted in a significant decrease in NRG-induced proliferation of MCF7 cells. Analysis of Erk5 in several human tumor cell lines indicated that a constitutively active form of this kinase was present in the BT474 and SKBR3 cell lines, which also expressed activated forms of ErbB2, ErbB3, and ErbB4. Treatments aimed at decreasing the activity of these receptors caused Erk5 inactivation, indicating that the active form of Erk5 present in BT474 and SKBR3 cells was due to a persistent positive stimulus originating at the ErbB receptors. In BT474 cells expression of the dominant negative form of Erk5 resulted in reduced proliferation, indicating that in these cells Erk5 was also involved in the control of proliferation. Taken together, these results suggest that Erk5 may play a role in the regulation of cell proliferation by NRG receptors and indicate that constitutively active NRG receptors may induce proliferative responses in cancer cells through this MAPK pathway.

This article has been cited by other articles:

• Esparis-Ogando, A., Ocana, A., Rodriguez-Barrueco, R., Ferreira, L., Borges, J., Pandiella, A. (2008). Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol 0: mdn406v1-mdn406 [Abstract] [Full Text]  
• Dorado, F., Velasco, S., Esparis-Ogando, A., Pericacho, M., Pandiella, A., Silva, J., Lopez-Novoa, J. M., Rodriguez-Barbero, A. (2008). The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. Nephrol Dial Transplant 0: gfn333v1-gfn333 [Abstract] [Full Text]  
• Montero, J. C., Lopez-Perez, R., San Miguel, J. F., Pandiella, A. (2008). Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. haematol 93: 851-859 [Abstract] [Full Text]  
• Ostrander, J. H., Daniel, A. R., Lofgren, K., Kleer, C. G., Lange, C. A. (2007). Breast Tumor Kinase (Protein Tyrosine Kinase 6) Regulates Heregulin-Induced Activation of ERK5 and p38 MAP Kinases in Breast Cancer Cells. Cancer Res. 67: 4199-4209 [Abstract] [Full Text]  
• Cude, K., Wang, Y., Choi, H.-J., Hsuan, S.-L., Zhang, H., Wang, C.-Y., Xia, Z. (2007). Regulation of the G2-M cell cycle progression by the ERK5-NF{kappa}B signaling pathway. J. Cell Biol. 177: 253-264 [Abstract] [Full Text]  
• Montero, J. C., Rodriguez-Barrueco, R., Yuste, L., Juanes, P. P., Borges, J., Esparis-Ogando, A., Pandiella, A. (2007). The Extracellular Linker of pro-Neuregulin-{alpha}2c Is Required for Efficient Sorting and Juxtacrine Function. Mol. Biol. Cell 18: 380-393 [Abstract] [Full Text]  
• Garaude, J., Cherni, S., Kaminski, S., Delepine, E., Chable-Bessia, C., Benkirane, M., Borges, J., Pandiella, A., Iniguez, M. A., Fresno, M., Hipskind, R. A., Villalba, M. (2006). ERK5 Activates NF-{kappa}B in Leukemic T Cells and Is Essential for Their Growth In Vivo. J. Immunol. 177: 7607-7617 [Abstract] [Full Text]  
• Kondoh, K., Terasawa, K., Morimoto, H., Nishida, E. (2006). Regulation of nuclear translocation of extracellular signal-regulated kinase 5 by active nuclear import and export mechanisms.. Mol. Cell. Biol. 26: 1679-1690 [Abstract] [Full Text]  
• Wu, Y., Kajdacsy-Balla, A., Strawn, E., Basir, Z., Halverson, G., Jailwala, P., Wang, Y., Wang, X., Ghosh, S., Guo, S.-W. (2006). Transcriptional Characterizations of Differences between Eutopic and Ectopic Endometrium. Endocrinology 147: 232-246 [Abstract] [Full Text]  
• Hayashi, M., Fearns, C., Eliceiri, B., Yang, Y., Lee, J.-D. (2005). Big Mitogen-Activated Protein Kinase 1/Extracellular Signal-Regulated Kinase 5 Signaling Pathway Is Essential for Tumor-Associated Angiogenesis. Cancer Res. 65: 7699-7706 [Abstract] [Full Text]  
• Yuste, L., Montero, J. C., Esparis-Ogando, A., Pandiella, A. (2005). Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin. Cancer Res. 65: 6801-6810 [Abstract] [Full Text]  
• Sturla, L.-M., Cowan, C. W., Guenther, L., Castellino, R. C., Kim, J. Y.H., Pomeroy, S. L. (2005). A Novel Role for Extracellular Signal-Regulated Kinase 5 and Myocyte Enhancer Factor 2 in Medulloblastoma Cell Death. Cancer Res. 65: 5683-5689 [Abstract] [Full Text]  
• Yuste, L., Esparis-Ogando, A., Santos, E., Pandiella, A. (2005). Overexpression of RasN17 Fails to Neutralize Endogenous Ras in MCF7 Breast Cancer Cells. J Biochem 137: 731-739 [Abstract] [Full Text]  
• Carvajal-Vergara, X., Tabera, S., Montero, J. C., Esparis-Ogando, A., Lopez-Perez, R., Mateo, G., Gutierrez, N., Parmo-Cabanas, M., Teixido, J., San Miguel, J. F., Pandiella, A. (2005). Multifunctional role of Erk5 in multiple myeloma. Blood 105: 4492-4499 [Abstract] [Full Text]  
• Barros, J. C., Marshall, C. J. (2005). Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J. Cell Sci. 118: 1663-1671 [Abstract] [Full Text]  
• Ghosh, A. K., Steele, R., Ray, R. B. (2005). c-myc Promoter-binding Protein 1 (MBP-1) Regulates Prostate Cancer Cell Growth by Inhibiting MAPK Pathway. J. Biol. Chem. 280: 14325-14330 [Abstract] [Full Text]  
• Buschbeck, M., Ullrich, A. (2005). The Unique C-terminal Tail of the Mitogen-activated Protein Kinase ERK5 Regulates Its Activation and Nuclear Shuttling. J. Biol. Chem. 280: 2659-2667 [Abstract] [Full Text]  
• Kim, S.-W., Chao, T.-H., Xiang, R., Lo, J.-F., Campbell, M. J., Fearns, C., Lee, J.-D. (2004). Tid1, the Human Homologue of a Drosophila Tumor Suppressor, Reduces the Malignant Activity of ErbB-2 in Carcinoma Cells. Cancer Res. 64: 7732-7739 [Abstract] [Full Text]  
• Biswas, D. K., Shi, Q., Baily, S., Strickland, I., Ghosh, S., Pardee, A. B., Iglehart, J. D. (2004). NF-{kappa}B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc. Natl. Acad. Sci. USA 101: 10137-10142 [Abstract] [Full Text]  
• Thottassery, J. V., Sun, Y., Westbrook, L., Rentz, S. S., Manuvakhova, M., Qu, Z., Samuel, S., Upshaw, R., Cunningham, A., Kern, F. G. (2004). Prolonged Extracellular Signal-Regulated Kinase 1/2 Activation during Fibroblast Growth Factor 1- or Heregulin {beta}1-Induced Antiestrogen-Resistant Growth of Breast Cancer Cells Is Resistant to Mitogen-Activated Protein/Extracellular Regulated Kinase Kinase Inhibitors. Cancer Res. 64: 4637-4647 [Abstract] [Full Text]  
• Raviv, Z., Kalie, E., Seger, R. (2004). MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation. J. Cell Sci. 117: 1773-1784 [Abstract] [Full Text]  
• Cameron, S. J., Abe, J.-i., Malik, S., Che, W., Yang, J. (2004). Differential Role of MEK5{alpha} and MEK5{beta} in BMK1/ERK5 Activation. J. Biol. Chem. 279: 1506-1512 [Abstract] [Full Text]  
• Suarez, Y., Gonzalez, L., Cuadrado, A., Berciano, M., Lafarga, M., Munoz, A. (2003). Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Molecular Cancer Therapeutics 2: 863-872 [Abstract] [Full Text]  
• Sohn, S. J., Sarvis, B. K., Cado, D., Winoto, A. (2002). ERK5 MAPK Regulates Embryonic Angiogenesis and Acts as a Hypoxia-sensitive Repressor of Vascular Endothelial Growth Factor Expression. J. Biol. Chem. 277: 43344-43351 [Abstract] [Full Text]  
• Buschbeck, M., Eickhoff, J., Sommer, M. N., Ullrich, A. (2002). Phosphotyrosine-specific Phosphatase PTP-SL Regulates the ERK5 Signaling Pathway. J. Biol. Chem. 277: 29503-29509 [Abstract] [Full Text]  
• Pipaon, C., Gutierrez, P., Montero, J. C., Lorenzo, M., Eguiraun, A., De la Fuente, J. A., Pandiella, A., Leon, J., Ortiz, J. M. (2002). Mitogen-activated Protein Kinase Routes as Targets in the Action of Diaza-anthracene Compounds with a Potent Growth-inhibitory Effect on Cancer Cells. Molecular Cancer Therapeutics 1: 811-819 [Abstract] [Full Text]